As a handful of Ohio State Buckeyes began to make decisions about heading to the NFL draft, or returning for a final season ...

After having a successful IPO less than a year ago, this biotech innovator had notable insider transactions to close out 2025.

Learn how the stock replacement strategy lets investors use call options to match stock gains with less capital, offering ...

Through four ACC games, Virginia Tech men's basketball has split its conference slate, bookending consecutive losses to Wake ...

Keithen Drury has positions in Alphabet. The Motley Fool has positions in and recommends Alphabet, International Business ...

The yield of more than 8% does look attractive, but given that the stock is redeemable there are some concerns on share price ...

Some Gen Z-ers who first entered the markets during the pandemic’s meme stock craze have grown up to become more patient ...

Nebius Group N.V. is a fully integrated AI infrastructure company with great management and a bright future. Learn more about ...

JPMorgan Chase (JPM) is pulling back from its recent record high amid today's bank selloff, and will report earnings before ...

The brand enjoys a strong 'mindshare,' as the term 'PayPal' is often used informally as a verb to refer to sending money ...

Both biotechs are a bit risky, but could benefit from clinical progress this year -- and the upside would be huge. CRISPR has ...

An analyst from JP Morgan persists with their Overweight rating on RTX, maintaining a target price of $200. Reflecting concerns, an analyst from UBS lowers its rating to Neutral with a new price ...